Skip to Content
Investing Specialists

Weekly Wrap: Our 529 Ratings and 15 Top-Quality Stocks

We recap the week on and note the most popular stocks, funds, and exchange-traded funds.

Editor's Picks
Rating the Top 529 College Savings Plans
We upgrade nine plans and downgrade eight, shaking up our Gold and Silver ratings.

15 Top-Quality Stocks
These names were recently added to the Morningstar Wide Moat Focus Index.

3 Good Reasons to Sell a Fund
How to make the call.

It's Open Enrollment Season. Have You Taken a Good Look at an HSA?
For high-income investors who are maxing out other tax-sheltered accounts, the high-deductible healthcare plan/HSA combo is close to a no-brainer.

Earnings Updates
Tide Has Turned on P&G's Sales Course, Shares Pricey
Wide-moat Procter & Gamble chalked up another quarter of strong sales and profit gains.

Tariffs Drive Retail Disruption at Narrow-Moat Hasbro
We view shares as overvalued, and we plan to increase our fair value estimate.

Texas Instruments Sees Stronger Trade Headwinds
We'd seek a wider margin of safety before investing in this wide-moat firm.

Tesla's Surprise Profit Blows Away Consensus
Tesla is a volatile name and fair value estimate changes may be frequent as its story changes.

Microsoft Reports Good Results and Mixed Guidance
We believe wide-moat Microsoft is firing on all cylinders and remains a relatively safe harbor.

Chipotle: More Than a Comeback Story, but Shares Rich
Our optimism is tempered by a market valuation that assumes unrealistic long-term expectations.

One-Day Shipping Weighs on Amazon
The wide-moat firm remains our top pick in online retail, with the pullback offering an entry point to invest.

Product Bugs Hinder Twitter's Q3 Growth
We recommend waiting for an additional margin of safety before investing in this very-high-uncertainty name.

Competition Hits McDonald's U.S. Comps
Our fair value estimate for the wide-moat firm remains intact, and shares are modestly undervalued.

Raising Our Fair Value Estimate for Biogen
We assign a 30% probability of approval of the wide-moat firm's Alzheimer's drug.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.